H Lundbeck A/S (LUN.CO)
22 May 2018
Wed, May 2 2018
BRIEF-H Lundbeck says FDA updates Trintellix label to include data showing improvement in processing speed
* REG-FDA UPDATES TRINTELLIX® (VORTIOXETINE) LABEL TO INCLUDE DATA SHOWING IMPROVEMENT IN PROCESSING SPEED, AN IMPORTANT ASPECT OF COGNITIVE FUNCTION IN ACUTE MAJOR DEPRESSIVE DISORDER (MDD)
* INTERIM CEO GOTZSCHE SAYS EXPECTS NEW CEO WILL BE NAMED WITHIN SIX MONTHS
COPENHAGEN, Feb 7 Danish drugmaker Lundbeck posted weaker than expected fourth quarter operating profit and gave a broad range for its 2018 financial guidance because of a range of uncertainties.
COPENHAGEN, Feb 7 Drugmaker Lundbeck's fourth-quarter operating profit came in at 932 million Danish crowns ($155.19 million), undershooting the 1.05 billion expected by analysts in a Reuters poll.
* LUNDBECK ENTERS RESEARCH PARTNERSHIP ON NOVEL TREATMENT OF SCHIZOPHRENIA
* LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)